Stocktoria
Tectonic Therapeutic, Inc. TECX
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2018-06-21
Tectonic Therapeutic, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $63.5M | $41.4M | $37.0M | $72.2M | $83.1M |
| Operating income | -$84.0M | -$58.0M | -$44.6M | -$105.4M | -$118.8M |
| Income tax | $1.2M | $0 | $0 | $0 | — |
| Net income | -$74.2M | -$58.0M | -$42.8M | -$105.9M | -$119.1M |
| EPS (diluted) | $-4.05 | $-6.83 | $-33.76 | $-2.42 | $-2.78 |
| Operating cash flow | -$60.1M | -$59.1M | -$40.7M | -$97.2M | -$98.0M |
| Free cash flow | -$60.3M | -$59.2M | -$41.0M | -$97.5M | -$100.5M |
| Cash & equivalents | $253.8M | $141.2M | $28.8M | $92.6M | $189.6M |
| Total assets | $261.0M | $152.9M | $39.4M | $103.9M | $203.8M |
| Total liabilities | $9.7M | $12.1M | $43.4M | $28.6M | $34.4M |
| Shareholders' equity | $251.3M | $140.8M | -$84.6M | -$45.7M | $169.5M |
Source: SEC EDGAR filings · CIK 0001681087 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.